News
KPRX
3.500
+0.40%
0.014
Weekly Report: what happened at KPRX last week (1125-1129)?
Weekly Report · 5d ago
Weekly Report: what happened at KPRX last week (1118-1122)?
Weekly Report · 11/25 11:27
Weekly Report: what happened at KPRX last week (1111-1115)?
Weekly Report · 11/18 11:23
Kiora Pharmaceuticals: Strategic Advancements and Financial Stability Justify Buy Rating
TipRanks · 11/12 18:05
Kiora Pharmaceuticals Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 11/12 10:16
HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $10 Price Target
Benzinga · 11/12 10:06
Kiora Pharmaceuticals’ Promising Growth Prospects: Buy Rating Backed by Clinical Advancements and Strong Financial Position
TipRanks · 11/11 17:25
Weekly Report: what happened at KPRX last week (1104-1108)?
Weekly Report · 11/11 11:38
KIORA PHARMACEUTICALS, INC. Quarterly Report on Form 10-Q For the Quarterly Period Ended September 30, 2024
Press release · 11/08 23:07
Kiora Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters · 11/08 20:59
Kiora Pharmaceuticals GAAP EPS of -$0.81 misses by $0.05
Seeking Alpha · 11/08 12:26
KIORA PHARMACEUTICALS - EXPECTED RUNWAY INTO 2027, EXCLUDING ANY POTENTIAL PARTNERSHIP MILESTONES
Reuters · 11/08 12:03
KIORA PHARMACEUTICALS INC <KPRX.O> Q3 SHR VIEW $-0.76, REV VIEW $7000.00 -- LSEG IBES DATA
Reuters · 11/08 12:03
KIORA PHARMACEUTICALS INC - QTRLY SHR LOSS $0.81
Reuters · 11/08 12:03
Weekly Report: what happened at KPRX last week (1028-1101)?
Weekly Report · 11/04 11:35
Positive Developments and Strategic Partnerships Propel Kiora Pharmaceuticals to a Buy Rating
TipRanks · 10/30 19:45
Kiora Pharmaceuticals gets approval to initiate mid-stage trial for eye disorder treatment
Seeking Alpha · 10/29 12:43
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial
TipRanks · 10/29 11:28
KIORA PHARMACEUTICALS: RECEIVES IND APPROVAL TO INITIATE ABACUS-2, A PHASE 2 CLINICAL TRIAL OF KIO-301 FOR TREATMENT OF RETINITIS PIGMENTOSA
Reuters · 10/29 11:17
KIORA PHARMACEUTICALS: DOSING OF FIRST PATIENT WITH KIO-301 IS EXPECTED TO BEGIN NEXT YEAR
Reuters · 10/29 11:17
More
Webull provides a variety of real-time KPRX stock news. You can receive the latest news about KIORA PHARMACEUTICALS INC through multiple platforms. This information may help you make smarter investment decisions.
About KPRX
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).